208 related articles for article (PubMed ID: 30037875)
1. Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database.
Tung CH; Lai NS; Li CY; Tsai SJ; Chen YC; Chen YC
BMJ Open; 2018 Jul; 8(7):e021747. PubMed ID: 30037875
[TBL] [Abstract][Full Text] [Related]
2. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
Lin SY; Chen TC; Lu PL; Lin CY; Lin WR; Yang YH; Chen YH
BMC Infect Dis; 2014 Dec; 14():705. PubMed ID: 25523602
[TBL] [Abstract][Full Text] [Related]
3. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
Hsu CS; Kao JH; Chao YC; Lin HH; Fan YC; Huang CJ; Tsai PS
Aliment Pharmacol Ther; 2013 Aug; 38(4):415-23. PubMed ID: 23802888
[TBL] [Abstract][Full Text] [Related]
4. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.
Hsu CS; Huang CJ; Kao JH; Lin HH; Chao YC; Fan YC; Tsai PS
PLoS One; 2013; 8(7):e70458. PubMed ID: 23894660
[TBL] [Abstract][Full Text] [Related]
5. A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
Chen YC; Hwang SJ; Li CY; Wu CP; Lin LC
Medicine (Baltimore); 2015 Aug; 94(32):e1334. PubMed ID: 26266379
[TBL] [Abstract][Full Text] [Related]
6. Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
Chou SM; Yeh HJ; Lin TM; Chang YS; Hsu HC; Shen YC; Kuo TT; Chen JH; Chen SC; Chang CC
Front Immunol; 2022; 13():992819. PubMed ID: 36275719
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
Hsu WF; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Tsai PC; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
Sci Rep; 2020 Mar; 10(1):5372. PubMed ID: 32214132
[TBL] [Abstract][Full Text] [Related]
9. The Unraveled Link Between Antiviral Therapy and Heart Failure Hospitalization in Chronic Hepatitis C Virus Infection - A Nationwide Cohort Study.
Lin MS; Chung CM; Chang ML; Chen MY; Chang ST; Chu PH; Chen TH; Lin WY; Huang TJ; Lin YS
Circ J; 2018 May; 82(6):1623-1631. PubMed ID: 29503408
[TBL] [Abstract][Full Text] [Related]
10. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
Hsu YC; Lin JT; Ho HJ; Kao YH; Huang YT; Hsiao NW; Wu MS; Liu YY; Wu CY
Hepatology; 2014 Apr; 59(4):1293-302. PubMed ID: 24122848
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in taiwan.
Su FH; Wu CS; Sung FC; Chang SN; Su CT; Shieh YH; Yeh CC
PLoS One; 2014; 9(11):e113579. PubMed ID: 25415338
[TBL] [Abstract][Full Text] [Related]
12. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
Su TH; Yang HC; Tseng TC; Chou SW; Lin CH; Liu CH; Liu CJ; Chen CL; Kao JH
Mov Disord; 2019 Dec; 34(12):1882-1890. PubMed ID: 31505068
[TBL] [Abstract][Full Text] [Related]
14. Association of Interferon Alpha Receptor 1 with sustained virological response in hepatitis C and B co-infected patients.
Asim M; Rashid A; Majeed A; Wahid M; Razak S; Jamil A
J Pak Med Assoc; 2017 Jul; 67(7):980-985. PubMed ID: 28770872
[TBL] [Abstract][Full Text] [Related]
15. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
[TBL] [Abstract][Full Text] [Related]
16. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Zangneh HF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Hepatol; 2014 Sep; 61(3):482-91. PubMed ID: 24780302
[TBL] [Abstract][Full Text] [Related]
17. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
Tan SS; Adlin Nadia Z
Med J Malaysia; 2017 Jun; 72(3):165-174. PubMed ID: 28733564
[TBL] [Abstract][Full Text] [Related]
18. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
20. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
